Finpecia 保康絲 1mg 防脫口服 100片(10片x10) / 100天 Finasteride[代購]

香港保康絲Finpecia 1mg價錢與副作用和原廠保康絲同成份含有Finpecia 1mg 實驗證實印度保康絲具有相同療效。由印度Cipla生產

【產品規格】 大盒包裝，每盒100片（10板×10片）。每片含量為1MG Finasteride。

【服用方法】 口服：1mg/次，1次/天，3個月為一療程。

【產品簡介】

Finpecia－1MG Finasteride，柔沛 Propecia 和波期卡 Proscar 最完美替代產品，享受較低價格的同時再也不用為了切分而煩惱了。

Finpecia, 由印度廠家Cipla生產，因為印度國家的法律衡量產品專利標準是製作方法而非產品成分，所以印度可以生產很多歐美國家的專利產品，除了針對男性脂溢型脫 髮的專利產品Finpecia外，像「威而剛」等很多西方國家的專利產品，都可以在印度買到相同配方的低廉替代品。

 

大家聽到印度的廠家可能會有些懷疑，這就像老外看到中國的產品就會懷疑質量是否過關一樣，是偏見和不瞭解造成的。大 家可以在Google上搜索下 Finpecia或Cipla，Finpecia由於使用方便，價格較低廉，在歐美、日本等地有眾多發友使用，也有良好的反饋。Cipla是著名的印度上 市企業，也是歐洲認可的非本土最大的產品供應商，同時與美國的大型治藥企業也有著長期的合作。

 

保康絲使用指南

建議劑量為一天一次，每次口服1毫克。Finasteride 可與食物併服或空腹服用。一般而言，須每天服藥持續三個月以上，才會看到初步療效。

保康絲用途是什麼？

保康絲用於治療男性型脫髮，這涉及頭皮毛髮逐漸稀疏，最明顯的表現為男性頭頂的髮際線後退或禿頂。保康絲有時以較高劑量治療前列腺肥大propecia，也稱為良性前列腺增生 (BPH)。

男性脫髮的原因是什麼？

男性型脫髮是脫髮的最常見原因。它通常是一種遺傳病。隨著病情的發展，頭髮的自然生長周期減弱，毛囊收縮，導致頭髮變得更短、更細。這種脫髮的確切原因尚不清楚，但它與激素二氫睾酮 (DHT) 的產生有關。抑制 DHT 產生的治療有時可有效減緩、停止或逆轉雄激素性脫髮引起的脫髮。

保康絲與Minoxidil合用效果更好嗎？

是的。臨床證明保康絲和Minoxidil 一起使用效果更好

保康絲需要多久時間才能起作用？

保康絲治療脫髮，可能需要 3-6 個月才能開始看到效果。通常需要近 12 個月的時間看到最好的結果。保康絲效果一旦被您的身體吸收，就會開始發揮作用。這意味著保康絲開始阻止睾丸激素的轉化並降低 DHT 水平。

但是，頭髮需要經毛髮生長周期生長。您也不應該期望在幾個月內看到頭髮有任何變化，即使您按照指示使用藥物也是如此。請放心，保康絲正在積極發揮作用。隨著時間的推移，保康絲開始在您的體內積聚適量的每日劑量就足以顯著減少 DHT 的產生並保護您的頭髮。

 

【英文原廠說明書】

Finpecia

Finasteride Tablets USP

COMPOSITION

FINPECIATablets

Each film-coated tablet contains:

Finasteride USP …………… 1 mg

 

Colours: Titanium Dioxide and Quinoline Yellow WS

 

DOSAGE FORM

 

Film-coated Tablet

 

PHARMACOLOGY

 

Pharmacodynamics

 

Finasteride, a synthetic 4- azasteroid compound, is a specific inhibitor of 5 alpha- reductase, an intracellular enzyme that converts androgenic testosterone into 5alpha-dihydrotestosterone (DHT). Administration of finasteride 1 mg decreases scalp and serum DHT concentration, increased amounts of which are thought to be responsible for male pattern hair loss (androgenetic alopecia).

 

Pharmacokinetics

 

Absorption

 

In a study in 15 healthy young male subjects, the mean bioavailability of finasteride

 

1 mg tablets was 65% (range: 26–170%), based on the ratio of area under the curve (AUC) relative to an intravenous reference dose. At steady state following dosing with 1 mg/day (n=12), maximum finasteride plasma concentration averaged 9.2 ng/mL (range: 4.9–13.7 ng/mL) and was reached 1 to 2 hours post-dose. Bioavailability of finasteride was not affected by food.

 

Distribution

 

Mean steady-state volume of distribution was 76 litres (range: 44–96 litres; n=15). Approximately 90% of circulating finasteride is bound to plasma proteins. There is a slow accumulation phase for finasteride after multiple dosing.

 

Finasteride has been found to cross the blood-brain barrier.

 

Semen levels have been measured in 35 men taking finasteride 1 mg/day for 6 weeks and in 60% (21 of 35) of the samples, finasteride levels were undetectable (<0.2 ng/mL). The mean finasteride level was 0.26 ng/mL and the highest level measured was 1.52 ng/mL. Using the highest semen level measured and assuming 100% absorption from a 5 mL ejaculate per day, human exposure through vaginal absorption would be up to 7.6 ng per day, which is 750 times lower than the exposure from the no-effect dose for developmental abnormalities in Rhesus monkeys and 650-fold less than the dose of finasteride (5 μg), which had no effect on circulating DHT levels in men.

 

Metabolism

 

Finasteride is extensively metabolized in the liver, primarily via the cytochrome P450 3A4 enzyme subfamily. Two metabolites, the t-butyl side chain monohydroxylated and monocarboxylic acid metabolites, have been identified that possess no more than 20% of the 5alpha-reductase inhibitory activity of finasteride.

 

Excretion

 

Following an oral dose of 14 C-finasteride in men (n=6), a mean of 39% (range: 32–46%) of the dose was excreted in the urine in the form of metabolites; 57% (range: 51–64%) was excreted in the faeces.

 

Mean terminal half-life is approximately 5 to 6 hours in men, 18 to 60 years of age, and 8 hours in men more than 70 years of age.

 

INDICATIONS

 

FINPECIAis indicated for the treatment of male pattern hair loss (androgenetic alopecia) inMEN ONLY. Safety and efficacy have been demonstrated in men between the ages of 18 to 41 years with mild to moderate hair loss of the vertex and anterior mid-scalp area.FINPECIAis not indicated in women and children.

 

DOSAGE AND ADMINISTRATION

 

The recommended dosage is 1 mg once a day, with or without meals. In general, daily use for 3 months or more is necessary before benefit is observed. Continued use is recommended to sustain benefits. Withdrawal of treatment leads to a reversal of effect within 12 months.

 

CONTRAINDICATIONS

 

Hypersensitivity to any ingredient in the formulation.FINPECIAuse is contraindicated in women when they are or may potentially be pregnant.

 

WARNINGS AND PRECAUTIONS

 

Drug Interaction

 

No drug interactions of clinical importance have been identified. Finasteride does not appear to affect the cytochrome P450-linked drug metabolizing enzyme system. Compounds that have been tested in men include antipyrine, digoxin, propranolol, theophylline, and warfarin and no interactions were found.

 

Renal Impairment

 

No dosage adjustments are required.

 

Hepatic Impairment

 

To be used with caution since finasteride is metabolized extensively in the liver.

 

Pregnancy

 

Pregnancy Category X

 

Women should not handle crushed or brokenFINPECIAtablets when they are pregnant or may potentially be pregnant because of the possibility of absorption of finasteride and the subsequent potential risk to a male foetus.

 

Lactation

 

It is not known whether finasteride is excreted in human milk.

 

Paediatric Use

 

FINPECIA is not indicated for use in paediatric patients.

 

UNDESIRABLE EFFECTS

 

FINPECIAis generally well tolerated and side effects have usually been mild and transient. These include decreased libido, erectile dysfunction, and ejaculation disorders (primarily, decreased volume of ejaculate), breast tenderness and enlargement, hypersensitivity reactions, including rash, pruritus, urticaria, and swelling of the lips and face, and testicular pain.

 

OVERDOSAGE

 

In clinical studies, single doses of finasteride up to 400 mg and multiple doses of finasteride up to 80 mg/day for 3 months did not result in adverse reactions. Until further experience is obtained, no specific treatment for an overdose with finasteride can be recommended.

 

Significant lethality was observed in male and female mice at single oral doses of

 

1,500 mg/m2(500 mg/kg) and in female and male rats at single oral doses of

 

2,360 mg/m2(400 mg/kg) and 5,900 mg/m 2 (1,000 mg/kg), respectively.

 

SHELF-LIFE

 

3 years

 

STORAGE AND HANDLING INSTRUCTIONS

 

Store in a dry place at room temperature.

 

PACKAGING INFORMATION

 

FINPECIA Tablets Blister pack of 10 tablets